Skip to main content

06.12.2019 | Original Article - Vascular Neurosurgery - Aneurysm

Evaluation of disease severity and treatment intensity as cost drivers for ruptured intracranial aneurysms

verfasst von: Herschel Wilde, Spencer Twitchell, Jared Reese, Jian Guan, Ilyas M. Eli, Michael Karsy, Philipp Taussky, Ramesh Grandhi, Richard H. Schmidt, William T. Couldwell

Erschienen in: Acta Neurochirurgica

Einloggen, um Zugang zu erhalten

Abstract

Background

Previous studies have not evaluated the impact of illness severity and postrupture procedures in the cost of care for intracranial aneurysms. We hypothesize that the severity of aneurysm rupture and the aggressiveness of postrupture interventions play a role in cost.

Methods

The Value Driven Outcomes database was used to assess direct patient cost during the treatment of ruptured intracranial aneurysm with clipping, coiling, and Pipeline flow diverters.

Results

One hundred ninety-eight patients (mean age 52.8 ± 14.1 years; 40.0% male) underwent craniotomy (64.6%), coiling (26.7%), or flow diversion (8.6%). Coiling was 1.4× more expensive than clipping (p = .005) and flow diversion was 1.7× more expensive than clipping (p < .001). More severe illness as measured by American Society of Anesthesia, Hunt/Hess, and Fisher scales incurred higher costs than less severe illness (p < .05). Use of a lumbar drain protocol to reduce subarachnoid hemorrhage and use of an external ventricular drain to manage intracranial pressure were associated with reduced (p = .05) and increased (p < .001) total costs, respectively. Patients with severe vasospasm (p < .005), those that received shunts (p < .001), and those who had complications (p < .001) had higher costs. Multivariate analysis showed that procedure type, length of stay, number of angiograms, vasospasm severity, disposition, and year of treatment were independent predictors of cost.

Conclusions

These results show for the first time that disease and vasospasm severity and intensity of treatment directly impact the cost of care for patients with aneurysms in the USA. Strategies to alter these variables may prove important for cost reduction.
Literatur
14.
18.
Zurück zum Zitat Moore JM, Adeeb N, Shallwani H, Gupta R, Patel AS, Griessenauer CJ, Youn R, Siddiqui A, Ogilvy CS, Thomas AJ (2017) A multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures. Neurosurgery 81:665–671. https://doi.org/10.1093/neuros/nyx079 CrossRefPubMed Moore JM, Adeeb N, Shallwani H, Gupta R, Patel AS, Griessenauer CJ, Youn R, Siddiqui A, Ogilvy CS, Thomas AJ (2017) A multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures. Neurosurgery 81:665–671. https://​doi.​org/​10.​1093/​neuros/​nyx079 CrossRefPubMed
24.
Zurück zum Zitat Sonig A, Shallwani H, Natarajan SK, Shakir HJ, Hopkins LN, Snyder KV, Siddiqui AH, Levy EI (2018) Better outcomes and reduced hospitalization cost are associated with ultra-early treatment of ruptured intracranial aneurysms: a US Nationwide Data Sample Study. Neurosurgery 82:497–505. https://doi.org/10.1093/neuros/nyx241 CrossRefPubMed Sonig A, Shallwani H, Natarajan SK, Shakir HJ, Hopkins LN, Snyder KV, Siddiqui AH, Levy EI (2018) Better outcomes and reduced hospitalization cost are associated with ultra-early treatment of ruptured intracranial aneurysms: a US Nationwide Data Sample Study. Neurosurgery 82:497–505. https://​doi.​org/​10.​1093/​neuros/​nyx241 CrossRefPubMed
Metadaten
Titel
Evaluation of disease severity and treatment intensity as cost drivers for ruptured intracranial aneurysms
verfasst von
Herschel Wilde
Spencer Twitchell
Jared Reese
Jian Guan
Ilyas M. Eli
Michael Karsy
Philipp Taussky
Ramesh Grandhi
Richard H. Schmidt
William T. Couldwell
Publikationsdatum
06.12.2019
Verlag
Springer Vienna
Erschienen in
Acta Neurochirurgica
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-019-04153-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.